BOARD of DIRECTORS
Cognos Therapeutics Inc.’s Board of Directors is comprised of leading individuals from business, medical research and scientific technology fields. Each serves as part of the company’s governing body and custodians of the company’s financial interests. Each member of the board assumes the responsibility to initiate and establish the policies to further the company’s goals and ambitions as well as to maintain a fiduciary responsibility for the investors.
Roger D. Kornberg, PhD
Dr. Roger Kornberg serves as Chairman of the Board of Directors at Cognos Therapeutics, Inc. Dr. Kornberg is a Nobel prize-winning American biochemist. He currently teaches and performs research at the Stanford University School of Medicine where he is a professor of structural biology.
Richard Alan Lerner, MD
Dr. Lerner is a leading authority in biomedical research. He is the Lita Annenberg Hazen Professor of Immunochemistry in the Department of Molecular Biology of The Scripps Research Institute.
Josh Shachar has been involved in the innovation and development of advanced technologies for private and government agencies for over 20 years. Josh also serves as the the Chief Innovation Officer for Cognos Therapeteuics, Inc.
Thomas Chen, MD, PhD
Dr. Thomas Chen is a physician, a board certified neurosurgeon, and the Director of Surgical Neuro-oncology at USC. Dr. Chen also serves as the company’s Chief of Neurosurgery and Oncology.
Eli Gang, MD, FACC, FACP
Dr. Gang is a Clinical Professor of Medicine at the UCLA Geffen School of Medicine, former co-director of the EP Lab at Cedars-Sinai Medical Center, a member of the Cedars-Sinai Heart Institute, and co-founder of Magnetecs Corporation
Frank Adell is a successful entrepreneur and business leader with over 30-years of experience in strategic planning. In addition to being a key member on the Cognos Board of Directors, Mr. Adell also serves as CEO to the company.